NCT07494305Phase 2Recruiting

Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.

Study sponsor: LB Pharmaceuticals Inc. · LBRX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-02Estimated
Enrollment · participants320Estimated
Source updated2026-07-27Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.